Recent drug repurposing approaches identified the small-molecule protein kinase inhibitors afatinib and neratinib as active substances in AML cell lines that rapidly degrade TRIB2, eliciting survival benefits [29]. The gene discussed is TRIB2; the disease is acute myeloid leukemia.